Biotech · Public company · Wilmington, DE, US
Inhibikase Therapeutics, Inc.
Ticker IKT · SEC CIK 0001750149
Track this companyFree. Adds Inhibikase Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline3
- IKT-001Phase 3 · Pulmonary Arterial HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- IkT-001ProPhase 1 · CMLClinicalTrials.gov · fetched Nov 12, 2026
- Imatinib MesylatePhase 1 · CMLClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)PHASE3 · RECRUITING · started Apr 23, 2026ClinicalTrials.gov NCT07365332 · fetched Nov 12, 2026
- A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mgPHASE1 · COMPLETED · started Dec 16, 2022ClinicalTrials.gov NCT05623774 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 26, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 29, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026